ARWR – arrowhead pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
12/2
08:04 am
arwr
Low
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a "buy" rating on the stock.
12/2
07:30 am
arwr
Low
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
12/1
04:00 pm
arwr
Low
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
12/1
11:42 am
arwr
Low
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a "buy" rating on the stock.
12/1
08:09 am
arwr
Medium
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
11/25/2025
04:00 pm
arwr
23.3%
MISS
8/7/2025
04:01 pm
arwr
2.2%
MISS
5/12/2025
04:01 pm
arwr
9.4%
BEAT
2/10/2025
04:01 pm
arwr
-5.2%
MISS
12/1
08:09 am
Reiterates
Buy
Buy
Chardan Capital
Medium
9.7%
12/1
07:26 am
Maintains
Buy
Buy
Chardan Capital
Medium
9.0%
11/26
09:52 am
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
High
14.6%
11/26
09:52 am
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
High
14.6%
11/20
07:42 am
Maintains
Neutral
Neutral
Goldman Sachs
Medium
-4.8%
12/5
04:01 pm
arwr
Low
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: PERRY MICHAEL S
12/1
06:10 pm
arwr
Medium
Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 28 Filed by: Ferrari Mauro
11/28
01:20 pm
arwr
Neutral
Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Ferrari Mauro
11/25
04:14 pm
arwr
High
Form 10-K ARROWHEAD PHARMACEUTICAL For: Sep 30
11/25
04:11 pm
arwr
High
Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25
Show more
Top News Gainers
3/18 Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm 23.9%
11/25 Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25 19.2%
12/2 Form 424B5 ARROWHEAD PHARMACEUTICAL 12.5%
3/19 Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 14 9.3%
11/25 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 8.8%
8/5 Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 05 6.8%
4/20 Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks [Yahoo! Finance News] 6.4%
11/7 Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 05 Filed by: Myszkowski Kenneth Allen 6.3%
5/8 Q2/2019 3/31/2019 EPS 0.240 ZacksConsensus 0.220 ActVsEst 0.020 - Beat 6.1%
8/19 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock. 5.4%
Top News Decliners
3/15 Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified? [Yahoo! Finance News] -16.8%
2/6 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $55.00. They now have a "neutral" rating on the stock. -13.5%
12/2 3 Soaring Biotech Stocks to Watch in December [The Motley Fool] -13.3%
1/21 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is now covered by analysts at Svb Leerink Llc. They set an "underperform" rating and a $32.00 price target on the stock. -10.5%
3/9 Why Arrowhead Pharmaceuticals Shares Dropped 15% in February [The Motley Fool] -7.5%
4/29 Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 27 Filed by: GIVEN BRUCE D -7.4%
10/23 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was given a new $46.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. -7.0%
8/22 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -6.9%
6/27 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. -6.8%
12/20 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease -6.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3